Position in NUVL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
320,529
+1931.2% QoQ
Ownership
0.406%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NUVL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Polar Asset Management Partners Inc. holds $46,847,679 across 13 Biotechnology names. NUVL ranks #6 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
322,467 | $42,801,044 | |
| 2 | RNA |
Atrium Therapeutics, Inc.
|
150,000 | $2,017,500 | |
| 3 | RANI |
Rani Therapeutics Holdings, Inc.
|
2,318,542 | $1,762,091 | |
| 4 | EXEL |
Exelixis, Inc.
|
4,908 | $267,044 | |
| 5 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
1,150,300 | $0 | |
| 6 | NUVL |
Nuvalent, Inc.
This page
|
320,529 | $0 | |
| 7 | OSRH |
OSR Health, Inc.
|
360,000 | $0 | |
| 8 | ASBP |
Aspire Biopharma Holdings, Inc.
|
138,536 | $0 |
All Filings in NUVL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | — | 320,529 | Shares | Sole | 2026-08-14 | |
| 2025-06-30 | — | 15,780 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | — | 19,130 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | — | 25,580 | Shares | Sole | 2025-02-25 | |
| 2024-09-30 | — | 68,780 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||